Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Isofol Medical AB: Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin
GOTHENBURG, Sweden, February 24, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results